Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Osteoporosis

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    November 2019
  1. HALPER-STROMBERG E, Gallo T, Champakanath A, Taki I, et al
    Bone Mineral Density across the Life-Span in Patients with Type 1 Diabetes.
    J Clin Endocrinol Metab. 2019 Nov 2. pii: 5611085. doi: 10.1210.
    PubMed     Text format     Abstract available


  2. LEDER BZ, Mitlak B, Hu MY, Hattersley G, et al
    Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    J Clin Endocrinol Metab. 2019 Nov 1. pii: 5610884. doi: 10.1210.
    PubMed     Text format     Abstract available


  3. RAMCHAND SK, David NL, Leder BZ, Tsai JN, et al
    Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT.
    J Clin Endocrinol Metab. 2019 Nov 1. pii: 5610890. doi: 10.1210.
    PubMed     Text format     Abstract available


    October 2019
  4. ANAGNOSTIS P, Kenanidis E, Potoupnis M, Tsiridis E, et al
    Letter to the Editor: "Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline."
    J Clin Endocrinol Metab. 2019 Oct 28. pii: 5607923. doi: 10.1210.
    PubMed     Text format    


  5. KENDLER D, Chines A, Clark P, Ebeling PR, et al
    Bone Mineral Density After Transitioning From Denosumab to Alendronate.
    J Clin Endocrinol Metab. 2019 Oct 26. pii: 5607536. doi: 10.1210.
    PubMed     Text format     Abstract available


  6. LI GH, Robinson-Cohen C, Sahni S, Au PC, et al
    Association of Genetic Variants Related to Serum Calcium Levels with Reduced Bone Mineral Density.
    J Clin Endocrinol Metab. 2019 Oct 25. pii: 5606940. doi: 10.1210.
    PubMed     Text format     Abstract available


  7. LYU H, Zhao SS, Solomon DH
    Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".
    J Clin Endocrinol Metab. 2019 Oct 25. pii: 5606941. doi: 10.1210.
    PubMed     Text format    


  8. GEUSENS P, Marin F, Kendler DL
    Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".
    J Clin Endocrinol Metab. 2019 Oct 25. pii: 5606939. doi: 10.1210.
    PubMed     Text format    


  9. SUGIYAMA T
    Letter to the Editor: "Exercise mitigates bone loss in women with severe obesity after Roux-en-Y gastric bypass: a randomized controlled trial".
    J Clin Endocrinol Metab. 2019 Oct 23. pii: 5602688. doi: 10.1210.
    PubMed     Text format    


  10. MURAI IH, Roschel H, Gualano B
    Response to Letter to the Editor: "Exercise mitigates bone loss in women with severe obesity after Roux-en-Y gastric bypass: a randomized controlled trial".
    J Clin Endocrinol Metab. 2019 Oct 23. pii: 5602687. doi: 10.1210.
    PubMed     Text format    


  11. MERLOTTI D, Rendina D, Muscariello R, Picchioni T, et al
    PREVENTIVE ROLE OF VITAMIN D SUPPLEMENTATION FOR ACUTE PHASE REACTION AFTER BISPHOSPHONATE INFUSION IN PAGET'S DISEASE.
    J Clin Endocrinol Metab. 2019 Oct 22. pii: 5601913. doi: 10.1210.
    PubMed     Text format     Abstract available


  12. CHILOIRO S, Antonella G, Frara S, Bima C, et al
    Effects of Pegvisomant and Pasireotide LAR on vertebral fractures in acromegaly resistant to First-Generation SRLs.
    J Clin Endocrinol Metab. 2019 Oct 15. pii: 5588033. doi: 10.1210.
    PubMed     Text format     Abstract available


    September 2019
  13. ZHAO Z, Wang L, Fu Z, Ji L, et al
    The prevalence of osteoporosis tested by quantitative computed tomography in patients with different glucose tolerances.
    J Clin Endocrinol Metab. 2019 Sep 23. pii: 5572675. doi: 10.1210.
    PubMed     Text format     Abstract available


    August 2019
  14. SUGIYAMA T
    Letter to the Editor: "Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use".
    J Clin Endocrinol Metab. 2019 Aug 13. pii: 5548914. doi: 10.1210/jc.2019-01650.
    PubMed     Text format    


  15. MAJOOR BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, et al
    Denosumab in Patients with Fibrous Dysplasia Previously Treated with Bisphosphonates.
    J Clin Endocrinol Metab. 2019 Aug 7. pii: 5544499. doi: 10.1210/jc.2018-02543.
    PubMed     Text format     Abstract available


  16. JAIN RK, Weiner MG, Zhao H, Williams KJ, et al
    Diabetes-related fracture risk is different in African Americans when compared to Hispanics and Caucasians.
    J Clin Endocrinol Metab. 2019 Aug 1. pii: 5540967. doi: 10.1210/jc.2019-00931.
    PubMed     Text format     Abstract available


    July 2019
  17. MURAI IH, Roschel H, Dantas WS, Gil S, et al
    Exercise mitigates bone loss in women with severe obesity after Roux-en-Y gastric bypass: a randomized controlled trial.
    J Clin Endocrinol Metab. 2019 Jul 19. pii: 5535689. doi: 10.1210/jc.2019-00074.
    PubMed     Text format     Abstract available


  18. MAI HT, Tran TS, Ho-Le TP, Center JR, et al
    Response to Letter to the Editor: Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention.
    J Clin Endocrinol Metab. 2019 Jul 12. pii: 5530991. doi: 10.1210/jc.2019-01457.
    PubMed     Text format    


  19. WEN Z, Chen R, Liu H
    Letter to the Editor: Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention.
    J Clin Endocrinol Metab. 2019 Jul 12. pii: 5530988. doi: 10.1210/jc.2019-01326.
    PubMed     Text format    


  20. LYU H, Zhao SS, Yoshida K, Tedeschi SK, et al
    Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use.
    J Clin Endocrinol Metab. 2019 Jul 2. pii: 5526755. doi: 10.1210/jc.2019-00924.
    PubMed     Text format     Abstract available


    June 2019
  21. CAI S, Zhu J, Sun L, Fan C, et al
    Association between urinary triclosan with bone mass density and osteoporosis in the US adult women, 2005-2010.
    J Clin Endocrinol Metab. 2019 Jun 25. pii: 5522022. doi: 10.1210/jc.2019-00576.
    PubMed     Text format     Abstract available


    May 2019
  22. MAI HT, Tran TS, Ho-Le TP, Center JR, et al
    Response to Letter to the Editor: Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention.
    J Clin Endocrinol Metab. 2019 May 22. pii: 5492494. doi: 10.1210/jc.2019-01016.
    PubMed     Text format    


  23. KHOSRAVI A, Mansournia MA
    Letter to the Editor: Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention.
    J Clin Endocrinol Metab. 2019 May 22. pii: 5492491. doi: 10.1210/jc.2019-00935.
    PubMed     Text format    


  24. SUGIYAMA T
    Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline".
    J Clin Endocrinol Metab. 2019 May 16. pii: 5489446. doi: 10.1210/jc.2019-01017.
    PubMed     Text format    


  25. BARRIONUEVO P, Gionfriddo MR, Castaneda-Guarderas A, Zeballos-Palacios C, et al
    Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review.
    J Clin Endocrinol Metab. 2019;104:1631-1636.
    PubMed     Text format     Abstract available


  26. EASTELL R, Rosen CJ, Black DM, Cheung AM, et al
    Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
    J Clin Endocrinol Metab. 2019;104:1595-1622.
    PubMed     Text format     Abstract available


    April 2019
  27. EASTELL R, Rosen CJ
    Response to Letter to the Editor: Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
    J Clin Endocrinol Metab. 2019 Apr 18. pii: 5473527. doi: 10.1210/jc.2019-00777.
    PubMed     Text format    


  28. RODRIGUEZ EG, Lamy O
    Letter to the Editor "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline."
    J Clin Endocrinol Metab. 2019 Apr 18. pii: 5473525. doi: 10.1210/jc.2019-00747.
    PubMed     Text format    


  29. PAZIANAS M
    Letter to the Editor: Dietary calcium intake and bone loss over 6 years in osteopenic postmenopausal women.
    J Clin Endocrinol Metab. 2019 Apr 16. pii: 5450711. doi: 10.1210/jc.2019-00785.
    PubMed     Text format    


  30. WON SH, Kim JH
    Letter to the Editor: Evidence of a causal effect of estradiol on fracture risk in men.
    J Clin Endocrinol Metab. 2019 Apr 16. pii: 5450710. doi: 10.1210/jc.2019-00736.
    PubMed     Text format    


  31. MAI HT, Tran TS, Ho-Le TP, Center JR, et al
    Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention.
    J Clin Endocrinol Metab. 2019 Apr 5. pii: 5427152. doi: 10.1210/jc.2018-02614.
    PubMed     Text format     Abstract available


    March 2019
  32. REID LJ, Muthukrishnan B, Patel D, Seckl JR, et al
    Predictors of nephrolithiasis, osteoporosis and mortality in primary hyperparathyroidism.
    J Clin Endocrinol Metab. 2019 Mar 27. pii: 5419224. doi: 10.1210/jc.2018-02483.
    PubMed     Text format     Abstract available


  33. BRISTOW SM, Horne AM, Gamble GD, Mihov B, et al
    Dietary calcium intake and bone loss over 6 years in osteopenic postmenopausal women.
    J Clin Endocrinol Metab. 2019 Mar 21. pii: 5393287. doi: 10.1210/jc.2019-00111.
    PubMed     Text format     Abstract available


    February 2019
  34. NAPOLI N, Conte C, Pedone C, Strotmeyer ES, et al
    Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults.
    J Clin Endocrinol Metab. 2019 Feb 25. pii: 5364431. doi: 10.1210/jc.2018-02539.
    PubMed     Text format     Abstract available


  35. WATTS NB, Grbic JT, Binkley N, Papapoulos S, et al
    Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years.
    J Clin Endocrinol Metab. 2019 Feb 13. pii: 5316168. doi: 10.1210/jc.2018-01965.
    PubMed     Text format     Abstract available


    January 2019
  36. CAULEY JA, Ruppert K, Lian Y, Finkelstein JS, et al
    Serum Sex Hormones and the Risk of Fracture across the Menopausal Transition: Study of Women's Health Across the Nation.
    J Clin Endocrinol Metab. 2019 Jan 23. pii: 5298592. doi: 10.1210/jc.2018-02047.
    PubMed     Text format     Abstract available


  37. VAVANIKUNNEL J, Charlier S, Becker C, Schneider C, et al
    Association between glycemic control and risk of fracture in diabetic patients: A nested case-control study.
    J Clin Endocrinol Metab. 2019 Jan 16. pii: 5244186. doi: 10.1210/jc.2018-01879.
    PubMed     Text format     Abstract available


    December 2018
  38. LYU H, Jundi B, Xu C, Tedeschi SK, et al
    Comparison of denosumab vs. bisphosphonates in osteoporosis patients: A meta-analysis of randomized controlled trials.
    J Clin Endocrinol Metab. 2018 Dec 10. pii: 5235617. doi: 10.1210/jc.2018-02236.
    PubMed     Text format     Abstract available


    September 2018
  39. KINDLER JM, Lappe JM, Gilsanz V, Oberfield S, et al
    Lumbar Spine Bone Mineral Apparent Density in Children: Results from the Bone Mineral Density in Childhood Study.
    J Clin Endocrinol Metab. 2018 Sep 27. pii: 5107297. doi: 10.1210/jc.2018-01693.
    PubMed     Text format     Abstract available


  40. TOURNIS S, Trovas G, Triantafyllopoulos IK, Balanika AP, et al
    Letter to the editor. Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy.
    J Clin Endocrinol Metab. 2018 Sep 26. pii: 5106939. doi: 10.1210/jc.2018-01638.
    PubMed     Text format    


  41. JEON YK, Kim IJ, Kim K
    Reply to a Letter to the Editor: "Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy".
    J Clin Endocrinol Metab. 2018 Sep 26. pii: 5106936. doi: 10.1210/jc.2018-02004.
    PubMed     Text format    


  42. MA J, Siminoski K, Alos N, Halton J, et al
    Impact of vertebral fractures and glucocorticoid exposure on height deficits in children during treatment for leukemia.
    J Clin Endocrinol Metab. 2018 Sep 20. pii: 5103424. doi: 10.1210/jc.2018-01083.
    PubMed     Text format     Abstract available


  43. NETHANDER M, Vandenput L, Eriksson AL, Windahl S, et al
    Evidence of a Causal Effect of Estradiol on Fracture Risk in Men.
    J Clin Endocrinol Metab. 2018 Sep 11. pii: 5094017. doi: 10.1210/jc.2018-00934.
    PubMed     Text format     Abstract available


    July 2018
  44. HAMILTON EJ, Drinkwater JJ, Chubb SAP, Rakic V, et al
    A ten-year prospective study of bone mineral density and bone turnover in males and females with type 1 diabetes.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055538. doi: 10.1210/jc.2018-00850.
    PubMed     Text format     Abstract available


  45. LIN SM, Wang JH, Liang CC, Huang HK, et al
    Statin use is associated with decreased osteoporosis and fracture risks in stroke patients.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047290. doi: 10.1210/jc.2018-00652.
    PubMed     Text format     Abstract available


  46. SHEN J, Griffith JF, Zhu TY, Tang P, et al
    Bone Mass, Microstucture And Strength Can Discriminate Vertebral Fracture In Patients on Long-Term Steroid Treatment.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047293. doi: 10.1210/jc.2018-00490.
    PubMed     Text format     Abstract available


    June 2018
  47. KIM K, Kim IJ, Pak K, Kim SJ, et al
    Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy.
    J Clin Endocrinol Metab. 2018 Jun 21. pii: 5041930. doi: 10.1210/jc.2017-02704.
    PubMed     Text format     Abstract available


  48. LEWIECKI EM, Blicharski T, Goemaere S, Lippuner K, et al
    A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    J Clin Endocrinol Metab. 2018 Jun 20. pii: 5040365. doi: 10.1210/jc.2017-02163.
    PubMed     Text format     Abstract available


    May 2018
  49. KIM SY, Kong IG, Lim H, Choi HG, et al
    Increased risk of sudden sensory neural hearing loss in osteoporosis: A longitudinal follow up study.
    J Clin Endocrinol Metab. 2018 May 28. pii: 5005943. doi: 10.1210/jc.2018-00717.
    PubMed     Text format     Abstract available


  50. BONE HG, Cosman F, Miller PD, Williams GC, et al
    ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2018 May 24. pii: 5001732. doi: 10.1210/jc.2018-00163.
    PubMed     Text format     Abstract available


  51. SUGIYAMA T
    Letter to the Editor: Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 2018 May 15. pii: 4995803. doi: 10.1210/jc.2018-00886.
    PubMed     Text format    


    April 2018
  52. DEMPSTER DW, Brown JP, Fahrleitner-Pammer A, Kendler D, et al
    Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970149. doi: 10.1210/jc.2017-02669.
    PubMed     Text format     Abstract available


    March 2018
  53. LIU L, Wen Y, Zhang L, Xu P, et al
    Assessing the associations of blood metabolites with osteoporosis: a Mendelian randomization study.
    J Clin Endocrinol Metab. 2018 Mar 1. pii: 4916908. doi: 10.1210/jc.2017-01719.
    PubMed     Text format     Abstract available


  54. MAKITIE RE, Hackl M, Niinimaki R, Kakko S, et al
    Altered MicroRNA Profile in Osteoporosis Caused by Impaired WNT Signaling.
    J Clin Endocrinol Metab. 2018 Mar 1. pii: 4916912. doi: 10.1210/jc.2017-02585.
    PubMed     Text format     Abstract available


    February 2018
  55. KHOSLA S, Farr JN, Kirkland JL
    Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis.
    J Clin Endocrinol Metab. 2018 Feb 7. pii: 4841935. doi: 10.1210/jc.2017-02694.
    PubMed     Text format     Abstract available


  56. KIM BJ, Kwak MK, Ahn SH, Kim H, et al
    Lower Trabecular Bone Score in Patients With Primary Aldosteronism: Human Skeletal Deterioration by Aldosterone Excess.
    J Clin Endocrinol Metab. 2018;103:615-621.
    PubMed     Text format     Abstract available


    January 2018

  57. CORRIGENDUM FOR "Identification of Novel Potentially Pleiotropic Variants Associated With Osteoporosis and Obesity Using the cFDR Method".
    J Clin Endocrinol Metab. 2018 Jan 22. pii: 4819317. doi: 10.1210/jc.2018-00141.
    PubMed     Text format    


  58. GOSSIEL F, Scott JR, Paggiosi MA, Naylor KE, et al
    The effect of teriparatide treatment on circulating periostin and its relationship to regulators of bone formation and BMD in postmenopausal women with osteoporosis.
    J Clin Endocrinol Metab. 2018 Jan 22. pii: 4819314. doi: 10.1210/jc.2017-00283.
    PubMed     Text format     Abstract available


  59. BERGMAN J, Nordstrom A, Nordstrom P
    Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study.
    J Clin Endocrinol Metab. 2018;103:306-313.
    PubMed     Text format     Abstract available


    December 2017
  60. SOUCEK O, Schonau E, Lebl J, Willnecker J, et al
    A 6-Year Follow-Up of Fracture Incidence and Volumetric Bone Mineral Density Development in Girls with Turner Syndrome.
    J Clin Endocrinol Metab. 2017 Dec 28. pii: 4780815. doi: 10.1210/jc.2017-02381.
    PubMed     Text format     Abstract available


  61. ANASTASILAKIS AD, Makras P, Pikilidou M, Tournis S, et al
    Changes of circulating micro-RNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 2017 Dec 22. pii: 4772360. doi: 10.1210/jc.2017-02406.
    PubMed     Text format     Abstract available


    November 2017
  62. HU Y, Tan LJ, Chen XD, Liu Z, et al
    Identification of Novel Potentially-pleiotropic Variants Associated With Osteoporosis and Obesity Using cFDR method.
    J Clin Endocrinol Metab. 2017 Nov 14. doi: 10.1210/jc.2017-01531.
    PubMed     Text format     Abstract available


  63. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Text format     Abstract available


  64. LEE RH, Sloane R, Pieper C, Lyles KW, et al
    Clinical fractures among older men with diabetes are mediated by diabetic complications.
    J Clin Endocrinol Metab. 2017 Nov 1. doi: 10.1210/jc.2017-01593.
    PubMed     Text format     Abstract available


  65. SINGH-OSPINA N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, et al
    Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2017;102:3904-3913.
    PubMed     Text format     Abstract available


    September 2017
  66. SAKKA S, Gafni RI, Davies JH, Clarke B, et al
    Bone structural characteristics and response to bisphosphonate treatment in children with Hajdu-Cheney Syndrome.
    J Clin Endocrinol Metab. 2017 Sep 8. doi: 10.1210/jc.2017-01102.
    PubMed     Text format     Abstract available


  67. SMEETS CCJ, van der Steen M, Renes JS, Hokken-Koelega ACS, et al
    Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study.
    J Clin Endocrinol Metab. 2017;102:3508-3516.
    PubMed     Text format     Abstract available


    July 2017
  68. SWANSON C, Shea SA, Wolfe P, Cain SW, et al
    Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans.
    J Clin Endocrinol Metab. 2017 Jul 26. doi: 10.1210/jc.2017-01147.
    PubMed     Text format     Abstract available


  69. BALASURIYA CND, Evensen KAI, Mosti MP, Brubakk AM, et al
    Peak Bone Mass and Bone Microarchitecture in Adults Born With Low Birth Weight Preterm or at Term: A Cohort Study.
    J Clin Endocrinol Metab. 2017;102:2491-2500.
    PubMed     Text format     Abstract available


    June 2017
  70. PASCHOU S, Dede AD, Anagnostis PG, Vryonidou A, et al
    Type 2 diabetes and osteoporosis: a guide to optimal management.
    J Clin Endocrinol Metab. 2017 Jun 21. doi: 10.1210/jc.2017-00042.
    PubMed     Text format     Abstract available


  71. LAMY O, Gonzalez-Rodriguez E, Aubry-Rozier B
    Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2112.
    PubMed     Text format    


  72. RAO SD, Qiu S, Dhaliwal R, Bhadada SK, et al
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2111.
    PubMed     Text format    


    May 2017
  73. VERROKEN C, Pieters W, Beddeleem L, Goemaere S, et al
    CORTICAL BONE SIZE DEFICIT IN ADULT PATIENTS WITH TYPE 1 DIABETES MELLITUS.
    J Clin Endocrinol Metab. 2017 May 22. doi: 10.1210/jc.2017-00620.
    PubMed     Text format     Abstract available


  74. SCHORR M, Marengi DA, Pulumo R, Yu E, et al
    Oxytocin and its relationship to body composition, bone mineral density and hip geometry across the weight spectrum
    J Clin Endocrinol Metab. 2017 May 10. doi: 10.1210/jc.2016-3963.
    PubMed     Text format     Abstract available


  75. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Response to Letter: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1782.
    PubMed     Text format    


  76. ZHANG Y, Xiao H, Sheng ZF
    Letter to the Editor: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1780-1781.
    PubMed     Text format    


    April 2017
  77. GONZALEZ RODRIGUEZ E, Lamy O, Stoll D, Metzger M, et al
    High evening cortisol level is associated with low TBS and increased prevalent vertebral fractures. OsteoLaus study.
    J Clin Endocrinol Metab. 2017 Apr 4. doi: 10.1210/jc.2016-3804.
    PubMed     Text format     Abstract available


  78. WESSELING-PERRY K, Makitie RE, Valimaki VV, Laine T, et al
    Osteocyte protein expression is altered in low-turnover osteoporosis caused by mutations in WNT1 and PLS3.
    J Clin Endocrinol Metab. 2017 Apr 3. doi: 10.1210/jc.2017-00099.
    PubMed     Text format     Abstract available


    March 2017
  79. CHEMAITILLY W, Li Z, Krasin MJ, Brooke RJ, et al
    Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort.
    J Clin Endocrinol Metab. 2017 Mar 24. doi: 10.1210/jc.2016-3723.
    PubMed     Text format     Abstract available


  80. VALDERRABANO RJ, Lee J, Lui LY, Hoffman AR, et al
    Older Men with Anemia Have Increased Fracture Risk Independent of Bone Mineral Density.
    J Clin Endocrinol Metab. 2017 Mar 20. doi: 10.1210/jc.2017-00266.
    PubMed     Text format     Abstract available


  81. WANG Y, Wactawski-Wende J, Sucheston-Campbell LE, Preus L, et al
    Gene-hormone therapy interaction and fracture risk in postmenopausal women.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2936.
    PubMed     Text format     Abstract available


  82. BURR DB, Lane JE, Howe TS, Ng AC, et al
    Response to PD Miller, Underdiagnosis and Undertreatment of Osteoporosis: The Battle To Be Won.
    J Clin Endocrinol Metab. 2017;102:1088-1089.
    PubMed     Text format    


  83. TROVAS G
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
    J Clin Endocrinol Metab. 2017;102:1086.
    PubMed     Text format    


    February 2017
  84. NOTSU M, Yamauchi M, Yamamoto M, Nawata K, et al
    Primary aldosteronism as a risk factor for vertebral fracture.
    J Clin Endocrinol Metab. 2017 Feb 9. doi: 10.1210/jc.2016-3206.
    PubMed     Text format    


    January 2017
  85. VUORIMIES I, Mayranpaa MK, Valta H, Kroger H, et al
    Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children with Osteogenesis Imperfecta.
    J Clin Endocrinol Metab. 2017 Jan 17. doi: 10.1210/jc.2016-3745.
    PubMed     Text format     Abstract available


  86. WATTS NB, Cauley JA, Jackson RD, LaCroix AZ, et al
    No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative.
    J Clin Endocrinol Metab. 2017;102:302-308.
    PubMed     Text format     Abstract available


    November 2016
  87. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Cortical bone area predicts incident fractures independently of areal bone mineral density in older men.
    J Clin Endocrinol Metab. 2016 Nov 22:jc20163177.
    PubMed     Text format     Abstract available


  88. PAPADAKIS G, Hans D, Gonzalez-Rodriguez E, Vollenweider P, et al
    The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.
    J Clin Endocrinol Metab. 2016 Nov 17:jc20162695.
    PubMed     Text format     Abstract available


  89. CHAWLA H, Saha S, Kandaswamy D, Sharma R, et al
    Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long term follow-up.
    J Clin Endocrinol Metab. 2016 Nov 4:jc20163292.
    PubMed     Text format     Abstract available


    October 2016
  90. VALIMAKI VV, Makitie O, Pereira R, Laine C, et al
    Teriparatide Treatment in Patients with WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis - A Pilot Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162423.
    PubMed     Text format     Abstract available


  91. LAMY O, Gonzalez-Rodriguez E, Stoll D, Hans D, et al
    Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20163170.
    PubMed     Text format     Abstract available


    September 2016
  92. ESCHE J, Johner S, Shi L, Schonau E, et al
    Urinary citrate, an index of acid-base status, predicts bone strength in youths and fracture risk in adult females.
    J Clin Endocrinol Metab. 2016 Sep 27:jc20162677.
    PubMed     Text format     Abstract available


    May 2016
  93. SHANBHOGUE VV, Finkelstein JS, Bouxsein ML, Yu EW, et al
    Association between insulin resistance and bone structure in non-diabetic postmenopausal women.
    J Clin Endocrinol Metab. 2016 May 31:jc20161726.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: